Financials data is unavailable for this security.
View more
Year on year Xvivo Perfusion AB grew revenues 43.88% from 415.29m to 597.54m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 398.29% net income growth from 18.43m to 91.82m.
Gross margin | 74.16% |
---|---|
Net profit margin | 17.28% |
Operating margin | 5.95% |
Return on assets | 5.95% |
---|---|
Return on equity | 6.84% |
Return on investment | 6.45% |
More ▼
Cash flow in SEKView more
In 2023, Xvivo Perfusion AB increased its cash reserves by 121.50%, or 299.54m. Cash Flow from Financing totalled 418.55m or 70.04% of revenues. In addition the company generated 46.29m in cash from operations while cash used for investing totalled 161.62m.
Cash flow per share | 6.15 |
---|---|
Price/Cash flow per share | 81.80 |
Book value per share | 64.28 |
---|---|
Tangible book value per share | 23.66 |
More ▼
Balance sheet in SEKView more
Current ratio | 4.13 |
---|---|
Quick ratio | 3.27 |
Total debt/total equity | 0.0134 |
---|---|
Total debt/total capital | 0.0133 |
More ▼
Growth rates in SEK
SmartText is unavailable
EPS growth(5 years) | 44.77 |
---|---|
EPS (TTM) vs TTM 1 year ago | 332.07 |